<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMIFOSTINE - amifostine injection, powder, lyophilized, for solution </strong><br>Sun Pharmaceutical Industries Limited<br></p></div>
<h1>Amifostine for Injection </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Amifostine for injection is an organic thiophosphate cytoprotective agent known chemically as 2-[(3-aminopropyl) amino] ethanethiol dihydrogen phosphate (ester) and has the following structural formula: <br></p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cd49351-6dde-4c85-be33-9a20bde785db&amp;name=amifostine-structure.jpg"></p>
<p>Amifostine is a white crystalline powder, which is freely soluble in water. Its molecular formula is C<span class="Sub">5</span>H<span class="Sub">15</span>N<span class="Sub">2</span>O<span class="Sub">3</span>PS and it has a molecular weight of 214.22.<br><br>Amifostine for Injection is the trihydrate form of amifostine and is supplied as a sterile powder requiring reconstitution for intravenous infusion. Each single-use 10 mL vial contains 500 mg of amifostine on the anhydrous basis.<br><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin. The ability of Amifostine to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure to cisplatin.<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First">Clinical pharmacokinetic studies show that Amifostine is rapidly
cleared from the plasma with a distribution half-life of &lt;1 minute
and an elimination half-life of approximately 8 minutes. Less than 10%
of Amifostine remains in the plasma 6 minutes after drug
administration. Amifostine is rapidly metabolized to an active free
thiol metabolite. A disulfide metabolite is produced subsequently and
is less active than the free thiol. After a 10-second bolus dose of 150
mg/m<span class="Sup">2</span> of Amifostine, renal excretion of the parent drug and
its two metabolites was low during the hour following drug
administration, averaging 0.69%, 2.64% and 2.22% of the administered
dose for the parent, thiol and disulfide, respectively. Measurable
levels of the free thiol metabolite have been found in bone marrow
cells 5 to 8 minutes after intravenous infusion of Amifostine.
Pretreatment with dexamethasone or metoclopramide has no effect on
Amifostine pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-2.2"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First"><span class="Bold">Chemotherapy for Ovarian Cancer. <br></span></p>
<p><span class="Bold"></span>A randomized controlled trial compared six cycles of cyclophosphamide 1000 mg/m<span class="Sup">2</span>, and cisplatin 100 mg/m<span class="Sup">2</span> with or without Amifostine pretreatment at 910 mg/m<span class="Sup">2</span>, in two successive cohorts of 121 patients with advanced ovarian cancer. In both cohorts, after multiple cycles of chemotherapy, pretreatment with<br>Amifostine significantly reduced the cumulative renal toxicity associated with cisplatin as assessed by the proportion of patients who had ≥ 40% decrease in creatinine clearance from pretreatment values, protracted elevations in serum creatinine (&gt;1.5 mg/dL), or severe <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Subgroup analyses suggested that the effect of Amifostine was present in patients who had received nephrotoxic antibiotics, or who had preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (and thus may have been at increased risk for significant <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>), as well as in patients who lacked these risks. Selected analyses of the effects of Amifostine in reducing the cumulative renal toxicity of cisplatin in the randomized ovarian cancer study are provided in TABLES <a href="#t1">1</a> and <a href="#t2">2</a>, below.</p>
<a name="t1"></a><table width="434.000">
<caption><span>TABLE 1 Proportion of Patients with ≥40% Reduction in Calculated Creatinine Clearance<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="27.9%">
<col width="28.8%">
<col width="25.8%">
<col width="17.5%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Creatinine clearance values were calculated using the Cockcroft-Gault formula, <span class="Italics">Nephron</span> 1976; 16:31-41.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">  </td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Amifostine+CP</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">CP</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">p-value<br>(2-sided)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">All Patients</td>
<td class="Botrule Rrule" align="center" valign="bottom">16/122 (13%)</td>
<td class="Botrule Rrule" align="center" valign="bottom">36/120 (30%)</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">First Cohort</td>
<td class="Botrule Rrule" align="center" valign="bottom">10/63</td>
<td class="Botrule Rrule" align="center" valign="bottom">20/58</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.018</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">Second Cohort</td>
<td class="Rrule" align="center" valign="bottom">6/59</td>
<td class="Rrule" align="center" valign="bottom">16/62</td>
<td class="Rrule" align="center" valign="bottom">0.026</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table width="664">
<caption><span>TABLE 2 NCI Toxicity Grades of Serum Magnesium Levels for Each Patient's Last Cycle of Therapy </span></caption>
<col width="23.2%">
<col width="12.3%">
<col width="13.3%">
<col width="13.3%">
<col width="13.3%">
<col width="12.3%">
<col width="12.3%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Based on 2-sided Mantel-Haenszel Chi-Square statistic.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">NCI-CTC Grade:<br>(mEq/L)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">  0    <br></span>&gt;1.4</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">     1      <br></span>≤1.4 to &gt;1.1</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">      2       <br></span>≤1.1 to &gt;0.8</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">      3       <br></span>≤0.8 to &gt;0.5</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"><span class="Underline">   4   <br></span>≤0.5</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">p-value</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Bold">All Patients<br></span>   <span class="Underline">Amifostine</span>+CP<br>   CP</td>
<td class="Botrule Rrule" align="center" valign="bottom">92<br>73</td>
<td class="Botrule Rrule" align="center" valign="bottom">13<br>18</td>
<td class="Botrule Rrule" align="center" valign="bottom">3<br>7</td>
<td class="Botrule Rrule" align="center" valign="bottom">0<br>5</td>
<td class="Botrule Rrule" align="center" valign="bottom">0<br>1</td>
<td class="Botrule Rrule" align="center" valign="middle">0.001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Bold">First Cohort<br></span>   <span class="Underline">Amifostine</span>+CP<br>   CP</td>
<td class="Botrule Rrule" align="center" valign="bottom">49<br>35</td>
<td class="Botrule Rrule" align="center" valign="bottom">10<br>8</td>
<td class="Botrule Rrule" align="center" valign="bottom">3<br>6</td>
<td class="Botrule Rrule" align="center" valign="bottom">0<br>3</td>
<td class="Botrule Rrule" align="center" valign="bottom">0<br>1</td>
<td class="Botrule Rrule" align="center" valign="middle"> 0.017</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Bold">Second Cohort<br></span>   <span class="Underline">Amifostine</span>+CP<br>   CP</td>
<td class="Rrule" align="center" valign="bottom">43<br>38</td>
<td class="Rrule" align="center" valign="bottom">3<br>10</td>
<td class="Rrule" align="center" valign="bottom">0<br>1</td>
<td class="Rrule" align="center" valign="bottom">0<br>2</td>
<td class="Rrule" align="center" valign="bottom">0<br>0</td>
<td class="Botrule Rrule" align="center" valign="middle">0.012</td>
</tr>
</tbody>
</table>
<p>In the randomized ovarian cancer study, Amifostine had no detectable effect on the antitumor efficacy of cisplatin-cyclophosphamide chemotherapy. Objective response rates (including pathologically confirmed complete remission rates), time to progression, and survival duration were all similar in the Amifostine and control study groups. The table below summarizes the principal efficacy findings of the randomized ovarian cancer study.<br><br></p>
<a name="t3"></a><table width="589">
<caption><span>TABLE 3 Comparison of Principal Efficacy Findings</span></caption>
<col width="40.1%">
<col width="28.0%">
<col width="31.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="middle"> </td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">    Amifostine +CP</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">CP</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Complete pathologic tumor response rate</span></td>
<td class="Botrule" align="center" valign="top">21.3%</td>
<td class="Botrule Rrule" align="center" valign="top">15.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Time to progression (months)<br></span>  Median (± 95% CI)  </td>
<td align="center" valign="bottom">15.8   (13.2, 25.1) </td>
<td class="Rrule" align="center" valign="bottom">18.1  (12.5, 20.4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  Mean (± Std error)</td>
<td align="center" valign="top">19.8   (±1.04)</td>
<td class="Rrule" align="center" valign="top">19.1   (±1.58)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">   Hazard ratio <br>   (95% Confidence Interval)</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"> .98 (.64, 1.4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Survival (months)<br></span>  Median (± 95% CI) </td>
<td align="center" valign="bottom">31.3  (28.3, 38.2)</td>
<td class="Rrule" align="center" valign="bottom">31.8  (26.3, 39.8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  Mean (± Std error)</td>
<td align="center" valign="top">33.7   (±2.03) </td>
<td class="Rrule" align="center" valign="top">34.3  (±2.04)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">  Hazard ratio <br>   (95% Confidence Interval)</td>
<td class="Rrule" align="center" colspan="2" valign="top"> .97 (.69, 1.32)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<span class="Bold">Amifostine for injection is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.</span><br><br>For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens is altered by Amifostine for injection. There are at present only limited data on the effects of Amifostine for injection on the efficacy of chemotherapy. Amifostine for injection should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit except in the context of a clinical study (see <a href="#s5">WARNINGS</a>).<br><br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>Amifostine for injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aminothiol compounds.<br><br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>1. Effectiveness of the Cytotoxic Regimen<br>Limited data are currently available regarding the preservation of antitumor efficacy when Amifostine is administered prior to cisplatin therapy in settings other than advanced ovarian cancer. Although some animal data suggest interference is possible, in most tumor models the antitumor effects of chemotherapy are not altered by amifostine. Amifostine should not be used in patients receiving chemotherapy for other malignancies in which chemotherapy can produce a significant survival benefit or cure (e.g., certain malignancies of germ cell origin), except in the context of a clinical study.<br><br>2. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><br>Patients who are hypotensive or in a state of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> should not receive Amifostine. Patients receiving Amifostine at doses recommended for chemotherapy should have antihypertensive therapy interrupted 24 hours preceding administration of Amifostine. Patients receiving Amifostine at doses recommended for chemotherapy who are taking antihypertensive therapy that cannot be stopped for 24 hours preceding Amifostine treatment, should not receive Amifostine.<br><br>Prior to Amifostine infusion patients should be adequately hydrated. During Amifostine infusion patients should be kept in a supine position. Blood pressure should be monitored every 5 minutes during the infusion, and thereafter as clinically indicated. It is important that the duration of the 910 mg/m2 infusion not exceed 15 minutes, as administration of Amifostine as a longer infusion is associated with a higher incidence of side effects. For infusion durations less than 5 minutes, blood pressure should be monitored at least before and immediately after the infusion, and thereafter as clinically indicated. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, patients should be placed in the Trendelenburg position and be given an infusion of normal saline using a separate i.v. line. During and after Amifostine infusion, care should be taken to monitor the blood pressure of patients whose antihypertensive medication has been interrupted since <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be exacerbated by discontinuation of antihypertensive medication and other causes such as i.v. hydration.<br><br>Guidelines for interrupting and restarting Amifostine infusion if a decrease in systolic blood pressure should occur are provided in the <a href="#s9">DOSAGE AND ADMINISTRATION</a> section. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur during or shortly after Amifostine infusion, despite adequate hydration and positioning of the patient (see <a href="#s7">ADVERSE REACTIONS</a> and <a href="#s6">PRECAUTIONS</a>). <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been reported to be associated with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, and in rare cases <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.<br><br>3. Cutaneous Reactions <br>Serious cutaneous reactions have been associated with Amifostine administration. Serious cutaneous reactions have included <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, toxoderma and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>. These reactions have been reported more frequently when Amifostine is used as a radioprotectant (see <a href="#s7">ADVERSE REACTIONS</a>). Some of these reactions have been fatal or have required hospitalization and/or discontinuance of therapy. Patients should be carefully monitored prior to, during and after Amifostine administration. Serious cutaneous reactions may develop weeks after initiation of Amifostine administration (see <a href="#s6">PRECAUTIONS</a>).<br><br>4. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><br>Allergic manifestations including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe cutaneous reactions have been associated with Amifostine administration. <br><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>Antiemetic medication should be administered prior to and in conjunction with Amifostine (see <a href="#s9">DOSAGE AND ADMINISTRATION</a>). When Amifostine is administered with highly emetogenic chemotherapy, the fluid balance of the patient should be carefully monitored.<br><br>5. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><br>Serum calcium levels should be monitored in patients at risk of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, such as those with <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or patients receiving multiple doses of Amifostine (see <a href="#s7">ADVERSE REACTIONS</a>). If necessary, calcium supplements can be administered.<br><br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>Patients should be adequately hydrated prior to the Amifostine infusion and blood pressure should be monitored (see <a href="#s9">DOSAGE AND ADMINISTRATION</a>).<br><br>The safety of Amifostine administration has not been established in elderly patients, or in patients with preexisting cardiovascular or cerebrovascular conditions such as <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>. Amifostine should be used with particular care in these and other patients in whom the common Amifostine adverse effects of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may be more likely to have serious consequences.<br><br>Prior to chemotherapy, Amifostine should be administered as a 15-minute infusion (see <a href="#s9">DOSAGE AND ADMINISTRATION</a>). Blood pressure should be monitored every 5 minutes during the infusion, and thereafter as clinically indicated.<br><br>Cutaneous Reactions <br><br>Cutaneous reactions may require permanent discontinuation of Amifostine or urgent dermatologic consultation and biopsy (see below).<br> <br>Cutaneous evaluation of the patient prior to each Amifostine administration should be performed with particular attention paid to the development of the following:<br><ul><li>Any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> involving the lips or involving mucosa not known to be due to another etiology (e.g., radiation <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, herpes simplex, etc.) </li></ul>
<ul>
<li>Erythematous, edematous, or <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous lesions</span> on the palms of the hands or soles of the feet and/or other cutaneous reactions on the trunk (front, back, abdomen) </li>
<li>Cutaneous reactions with associated <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other constitutional symptoms </li>
</ul>Amifostine should be permanently discontinued for serious or severe cutaneous reactions (see <a href="#s5">WARNINGS</a> and <a href="#s7">ADVERSE REACTIONS</a>) or for cutaneous reactions associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other constitutional symptoms not known to be due to another etiology. Amifostine should be withheld and dermatologic consultation and biopsy considered for cutaneous reactions or mucosal lesions of unknown etiology appearing outside of the injection site and for erythematous, edematous or <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous lesions</span> on the palms of the hand or soles of the feet. Reinitiation of Amifostine should be at the physician's discretion based on medical judgment and appropriate dermatologic evaluation.<br><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span><br>In case of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">acute allergic reactions</span> Amifostine should be immediately and permanently discontinued. Epinephrine and other appropriate measures should be available for treatment of serious allergic events such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. <br><br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>Special consideration should be given to the administration of Amifostine in patients receiving antihypertensive medications or other drugs that could cause or potentiate <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.<br><br>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>No long term animal studies have been performed to evaluate the carcinogenic potential of Amifostine. Amifostine was negative in the Ames test and in the mouse micronucleus test. The free thiol metabolite was positive in the Ames test with S9 microsomal fraction in the TA1535 <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> and at the TK locus in the mouse L5178Y cell assay. The metabolite was negative in the mouse micronucleus test and negative for clastogenicity in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>Pregnancy Category C. Amifostine has been shown to be embryotoxic in rabbits at doses of 50 mg/kg, approximately sixty percent of the recommended dose in humans on a body surface area basis. There are no adequate and well-controlled studies in pregnant women.<br><br>Amifostine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br><br>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>No information is available on the excretion of Amifostine or its metabolites into human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants, it is recommended that breast feeding be discontinued if the mother is treated with Amifostine.<br> </div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>The safety and effectiveness in pediatric patients have not been established.<br><br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>The clinical studies did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients.<br><br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<span class="Bold">Controlled Trials</span><br>In the randomized study of patients with ovarian cancer given Amifostine at a dose of 910 mg/m<span class="Sup">2</span> prior to chemotherapy, transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was observed in 62% of patients treated. The mean time of onset was 14 minutes into the 15-minute period of Amifostine infusion, and the mean duration was 6 minutes. In some cases, the infusion had to be prematurely terminated due to a more pronounced drop in systolic blood pressure. In general, the blood pressure returned to normal within 5 to 15 minutes. Fewer than 3% of patients discontinued Amifostine due to blood pressure reductions (see <a href="#t4">TABLE 4</a>).<br><a name="t4"></a><table width="495">
<caption><span>TABLE 4 Incidence of Common Adverse Events in Patients Receiving Amifostine</span></caption>
<col width="19.4%">
<col width="20.6%">
<col width="20.0%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>According to protocol-defined criteria. WR-1: requiring interruption of infusion; WR-38: drop of &gt;20mm Hg.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="middle"> </td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Phase III Ovarian Cancer<br>Trial (WR-1)<br>910 mg/m<span class="Sup">2</span> _____________________________ <br>Per Patient           Per Infusion </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>  </span>≥Grade 3<br>  All Grades</td>
<td class="Botrule Rrule" align="center" valign="bottom">36/122 (30%)<br>117/122 (96%)</td>
<td class="Botrule Rrule" align="center" valign="bottom">53/592 (9%)<br>520/592 (88%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><br>  </span>≥Grade 3<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><br>  All Grades</td>
<td class="Rrule" align="center" valign="bottom">10/122 (8%)<br>75/122 (61%)</td>
<td class="Rrule" align="center" valign="bottom">159/592 (27%)</td>
</tr>
</tbody>
</table>
<br><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> that requires interruption of the Amifostine infusion should be treated with fluid infusion and postural management of the patient (supine or Trendelenburg position). If the blood pressure returns to normal within 5 minutes and the patient is asymptomatic, the infusion may be restarted, so that the full dose of Amifostine can be administered. Short term, reversible <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> has been reported rarely.<br><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur frequently after Amifostine infusion and may be severe. In the ovarian cancer randomized study, the incidence of severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> on day 1 of cyclophosphamide-cisplatin chemotherapy was 10% in patients who did not receive Amifostine, and 19% in patients who did receive Amifostine. <br><br>Decrease in serum calcium concentrations is a known pharmacological effect of Amifostine. At the recommended doses, clinically significant <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> was not reported in the ovarian cancer study.<br><br>Other effects, which have been described during, or following Amifostine infusion are <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>/<span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling of warmth</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/feeling of <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span> and <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>. These effects have not generally precluded the completion of therapy.<br><br><span class="Bold">Clinical Trials and Pharmacovigilance Reports</span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> characterized by one or more of the following manifestations have been observed during or after Amifostine administration: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>. Cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> have been commonly reported during clinical trials and were generally non-serious. Serious, sometimes fatal <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and in rare cases, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have also occurred. Rare <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have also been reported.<br><br><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, usually brief systolic and diastolic, has been associated with one or more of the following adverse events: <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, respiratory and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have been observed during or after <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (See <a href="#s5">WARNINGS</a> and <a href="#s6">PRECAUTIONS</a>)<br><br>Rare cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/flutter and <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> have been reported. These are sometimes associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.<br><br>Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and exacerbations of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> have been observed rarely after Amifostine administration.<br><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been reported rarely. (See <a href="#s5">WARNINGS</a> and <a href="#s6">PRECAUTIONS</a>) <br><br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>In clinical trials, the maximum single dose of Amifostine was 1300 mg/m<span class="Sup">2</span>. No information is available on single doses higher than this in adults. In the setting of a clinical trial, pediatric patients have received single Amifostine doses of up to 2700 mg/m<span class="Sup">2</span>. At the higher doses, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and reversible <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> occurred.<br><br>Administration of Amifostine at 2 and 4 hours after the initial dose has not led to increased <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The most likely symptom of overdosage is <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, which should be managed by infusion of normal saline and other supportive measures, as clinically indicated.<br><br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s9"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>For Reduction of Cumulative Renal Toxicity with Chemotherapy: The recommended starting dose of Amifostine for injection is 910 mg/m<span class="Sup">2</span> administered once daily as a 15-minute i.v. infusion, starting 30 minutes prior to chemotherapy.<br><br>The 15-minute infusion is better tolerated than more extended infusions. Further reductions in infusion times for chemotherapy regimens have not been systematically investigated.<br><br>Patients should be adequately hydrated prior to Amifostine for injection infusion and kept in a supine position during the infusion. Blood pressure should be monitored every 5 minutes during the infusion, and thereafter as clinically indicated.<br><br>The infusion of Amifostine for injection should be interrupted if the systolic blood pressure decreases significantly from the baseline value as listed in the guideline below:<br><br><a name="t5"></a><table border="single" width="647">
<caption><span>Guideline for Interrupting Amifostine for injection Infusion Due to Decrease in Systolic Blood Pressure</span></caption>
<col width="38.2%">
<col width="12.7%">
<col width="11.9%">
<col width="12.7%">
<col width="11.9%">
<col width="12.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="5" valign="middle"><span class="Bold">Baseline Systolic Blood Pressure (mm Hg)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">&lt;100</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">100 to 119</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">120 to 139</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">140 to 179</span></td>
<td class="Botrule Rrule" align="center" valign="top">≥<span class="Bold">180</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Decrease in systolic blood pressure during infusion of Amifostine for injection (mm Hg)</td>
<td class="Rrule" align="center" valign="middle">20</td>
<td class="Rrule" align="center" valign="middle">25</td>
<td class="Rrule" align="center" valign="middle">30</td>
<td class="Rrule" align="center" valign="middle">40</td>
<td class="Botrule Rrule" align="center" valign="middle">50</td>
</tr>
</tbody>
</table>
<br>If the blood pressure returns to normal within 5 minutes and the patient is asymptomatic, the infusion may be restarted so that the full dose of Amifostine for injection may be administered. If the full dose of Amifostine for injection cannot be administered, the dose of Amifostine for injection for subsequent chemotherapy cycles should be 740 mg/m<span class="Sup">2</span>.<br><br>It is recommended that antiemetic medication, including dexamethasone 20 mg i.v. and a serotonin 5HT<span class="Sub">3</span> receptor antagonist, be administered prior to and in conjunction with Amifostine for injection. Additional antiemetics may be required based on the chemotherapy drugs administered.<br><br>Reconstitution<br>Amifostine for Injection is supplied as a sterile powder requiring reconstitution for intravenous infusion. Each single-use vial contains 500 mg of amifostine on the anhydrous basis. <br><br>Prior to intravenous injection, Amifostine for injection is reconstituted with 9.7 mL of sterile 0.9% Sodium Chloride Injection, USP. The reconstituted solution (500 mg amifostine/10 mL) is chemically stable for up to 5 hours at room temperature (approximately 25°C) or up to 24 hours under refrigeration (2°C to 8°C).<br><br>Amifostine for injection prepared in polyvinylchloride (PVC) bags at concentrations ranging from 5 mg/mL to 40 mg/mL is chemically stable for up to 5 hours when stored at room temperature (approximately 25°C) or up to 24 hours when stored under refrigeration (2°C to 8°C). CAUTION: Parenteral products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use if cloudiness or precipitate is observed.<br><br>Incompatibilities<br>The compatibility of Amifostine for injection with solutions other than 0.9% Sodium Chloride for Injection, or Sodium Chloride solutions with other additives, has not been examined. The use of other solutions is not recommended. <br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s10"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Amifostine for Injection USP is supplied as a sterile powder in 10 mL single-use vials (NDC 62756-581-40). Each single-use vial contains 500 mg of amifostine on the anhydrous basis. The vials are available packaged as follows:</p>
<p>1 pack - 1 vial per carton (NDC 62756-581-40).</p>
<p>3 pack - 3 vials per carton (NDC 62756-581-42).</p>
<p>Store the powder dosage form at Controlled Room Temperature 20°-25°C (68°-77°F) [See USP].</p>
<p>Distributed by:<br><span class="Bold">Caraco Pharmaceutical Laboratories, Ltd.</span><br>1150 Elijah McCoy Drive, Detroit, MI 48202<br><br>Manufactured by:<br><span class="Bold">Sun Pharmaceutical Ind. Ltd.</span><br>Acme Plaza, Andheri-Kurla Road,<br>Andheri (East), Mumbai -400 059, India.<br><br>PJPI0131A<br>ISS. 11/2009<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s11"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - vial label</h1>
<p class="First"><span class="Bold">NDC 62756-581-40<br>Amifostine for Injection USP<br>500 mg/vial<br>Sterile<br>Single use vials<br>For Intravenous Use<br>Rx only</span></p>
<p><img alt="Amifostine-vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cd49351-6dde-4c85-be33-9a20bde785db&amp;name=label.jpg"></p>
<p><br><span class="Bold"></span></p>
<p><span class="Bold"><br></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s12"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - showbox for 1 vial </h1>
<p class="First"><span class="Bold">NDC 62756-581-40<br>Amifostine for Injection USP<br>500 mg/vial<br>Sterile<br>Single use vials<br>For Intravenous Use<br>1 Vial<br>Rx only<br>Sun Pharmaceutical Industries Ltd.</span></p>
<p><img alt="Amifostine-showbox-1 vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cd49351-6dde-4c85-be33-9a20bde785db&amp;name=sb-1vial.jpg"></p>
<p><br><span class="Bold"></span></p>
<p><span class="Bold"><br></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s13"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - showbox for 3 vials </h1>
<p class="First"><span class="Bold">NDC 62756-581-42<br>Amifostine for Injection USP<br>500 mg/vial<br>Sterile<br>Single use vials<br>For Intravenous Use<br>3 Vials<br>Rx only<br>Sun Pharmaceutical Industries Ltd.</span></p>
<p><img alt="Amifostine-showbox-3 vials" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4cd49351-6dde-4c85-be33-9a20bde785db&amp;name=sb-3vials.jpg"></p>
<p><br><span class="Bold"></span></p>
<p><span class="Bold"><br></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMIFOSTINE 		
					</strong><br><span class="contentTableReg">amifostine injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62756-581</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMIFOSTINE</strong> (AMIFOSTINE) </td>
<td class="formItem">AMIFOSTINE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62756-581-40</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:62756-581-42</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077126</td>
<td class="formItem">03/14/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sun Pharmaceutical Industries Limited
							(650172430)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sun Pharmaceutical Industries Limited</td>
<td class="formItem"></td>
<td class="formItem">725959238</td>
<td class="formItem">manufacture, analysis</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2a527ed0-3af2-41eb-9e8f-5b4783b37259</div>
<div>Set id: 4cd49351-6dde-4c85-be33-9a20bde785db</div>
<div>Version: 1</div>
<div>Effective Time: 20091114</div>
</div>
</div> <div class="DistributorName">Sun Pharmaceutical Industries Limited</div></p>
</body></html>
